| Literature DB >> 28754148 |
Peter Agaba1, Janat Tumukunde2, J V B Tindimwebwa2, Arthur Kwizera2.
Abstract
BACKGROUND: The intensive care unit (ICU) admits critically ill patients requiring advanced airway, respiratory, cardiac and renal support. Despite the highly-specialized interventions, the mortality and morbidity is still high due to a number of reasons including nosocomial infections, which are the most likely complications in hospitalized patients with the rates being highest among ICU patients.Entities:
Keywords: Drug resistance; Intensive care unit; Mechanical ventilation; Nosocomial infections; Traumatic brain injury
Mesh:
Substances:
Year: 2017 PMID: 28754148 PMCID: PMC5534037 DOI: 10.1186/s13104-017-2695-5
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Fig. 1Study profile: two hundred and six patients were recruited. One hundred and eighteen were enrolled and 7 were lost to follow up. Only 111 patients were included in the analysis
Patient demographics
| N (%) | |
|---|---|
| Age group in years | |
| ≤30 | 44 (39.64) |
| 31–40 | 26 (23.42) |
| 41–50 | 9 (8.11) |
| 51–60 | 13 (11.71) |
| >60 | 19 (17.12) |
| Sex | |
| Female | 49 (44.14) |
| Male | 62 (55.86) |
| Referring within hospital | |
| No | 17 (15.31) |
| Yes | 94 (84.68) |
Fig. 2Distribution of admitting diagnosis in percentages. 22% of patients had traumatic brain injury, 19% had a sepsis related diagnosis, 19% respiratory failure and 13% a cerebral vascular accident. The rest fell into the categories of obstetrics, perioperative admissions, spinal cord injury, acute kidney injury or circulatory collapse
Organisms isolated from samples taken off at admission to the ICU
| Bacterial species | Sample | ||
|---|---|---|---|
| Blood | Tracheal | Urine | |
| N = 99 | N = 67 | N = 4 | |
| N (%) | N (%) | N (%) | |
|
| 1 (1.00) | 8 (11.94) | 0 |
|
| 5 (4.40) | 3 (4.48) | 0 |
|
| 1 (1.00) | 4 (5.97) | 0 |
|
| 0 | 3 (4.48) | 0 |
|
| 0 | 2 (2.99) | 0 |
|
| 0 | 5 (7.46) | 0 |
|
| 0 | 0 | 0 |
|
| 1 (1.00) | 0 | 0 |
|
| 2 (2.02) | 1 (1.49) | 0 |
|
| 0 | 1 (1.49) | 0 |
|
| 0 | 0 | 0 |
|
| 0 | 0 | 0 |
Susceptibility rates for organisms isolated from samples taken off at admission to the ICU
| Bacterial species from blood sample | Bacterial species from tracheal sample | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. susceptible/total number tested (%) | No. susceptible/total number tested (%) | |||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Amikacin (30 µg) | 1/1 (100) | – | 0/1 (0) | 1/1 (100) | 1/2 (50) | – | – | 2/2 (100) | 3/3 (100) | – | – | – |
| Augmentin (20/10 µg) | – | – | – | 0/1 (0) | 0/6 (0) | – | 1/5 (20) | – | – | 0/1 (0) | 0/2 (0) | – |
| Ampicillin (10µ) | – | – | – | 0/1 (0) | 0/7 (0) | – | 0/5 (0) | – | – | 0/1 (0) | 0/2 (0) | – |
| Cefotaxime (30 µg) | 0/1 (0) | – | – | – | 0/6 (0) | – | 0/1 (0) | – | – | 0/1 (0) | 1/2 (50) | |
| Cefuroxime (30 µg) | 0/1 (0) | – | – | 0/1 (0) | 0/6 (0) | 0/2 (0) | 0/5 (0) | – | – | 0/1 (0) | 0/2 (0) | – |
| Ceftazidime (30 µg) | 0/1 (0) | – | 1/1 (100) | 0/1 (0) | 1/6 (16.67) | 0/1 (0) | 0/4 (0) | 1/1 (100) | 2/2 (100) | 0/1 (0) | 1/2 (50) | – |
| Ceftriaxone (30 µg) | 0/1 (0) | – | – | 0/1 (0) | 0/6 (0) | 1/1 (100) | 0/5 (0) | – | – | – | 0/1 (0) | – |
| Cefepime (30 µg) | – | – | – | – | – | – | – | 1/1 (100) | 1/1 (100) | – | – | – |
| Ciprofloxacin (5 µg) | 0/1 (0) | 1/3 (33.33) | – | – | 2/6 (33.33) | 0/3 (0) | 0/4 (0) | 1/1 (100) | 2/2 (100) | 0/1 (0) | 1/2 (50) | 0/1 (0) |
| Chloramphenicol (5 µg) | 0/1 (0) | 1/3 (33.33) | – | – | 2/7 (28.57) | – | 0/4 (0) | – | – | 0/1 (0) | 1/2 (50) | 0/1 (0) |
| Co-trimoxazole (1.25/23.5 µg) | 0/1 (0) | 0/4 (0) | – | 0/1 (0) | 0/7 (0) | 0/2 (0) | 0/5 (0) | 0/3 (0) | – | 0/1 (0) | 0/2 (0) | 0/1 (0) |
| Erythromycin (15 µg) | – | 0/4 (0) | – | – | – | 0/2 (0) | – | – | – | – | – | 1/1 (100) |
| Oxacillin (1 µg) | – | 2/3 (66.66) | – | – | 0/2 (0) | – | – | – | – | – | 1/1 (100) | |
| Tetracycline (30 µg) | – | 1/1 (100) | 0/1 (0) | – | – | 2/2 (100) | – | – | – | – | – | 1/1 (100) |
| Penicillin G (10 µg) | – | 0/2 (0) | – | – | – | – | – | – | – | – | – | 0/1 (0) |
| Gentamicin (10 µg) | 0/1 (0) | 2/2 (100) | – | 0/1 (0) | 0/4 (0) | 1/1 (100) | 1/5 (20) | 2/2 (100) | 3/3 (100) | 0/1 (0) | 1/2 (0) | – |
| Imipenem (10 µg) | 1/1 (100) | – | – | 1/1 (100) | 7/7 (100) | 1/1 (100) | 5/5 (100) | – | 1/1 (100) | 1/1 (100) | 1/1 (100) | – |
| Meropenem (10 µg) | – | – | – | – | – | – | – | – | – | – | 1/1 (100) | – |
| Vancomycin (30 µg) | – | 1/1 (100) | – | – | – | 0/1 (0) | – | – | – | – | – | – |
K. pneu, Klebsiella pneumoniae; S. aureus, Staphylococcus aureus; A. spp., Acinetobacter species; C. freundi, Citrobacter freundi; Acineto, Acinetobacter species; Proteus, Proteus mirabilis; Enterobacter, Enterobacter species; Coagulase, Coagulase negative Staphylococcus
Bacterial organism isolated from samples taken off after 48–72 h of admission
| Bacterial species | No of isolates 52 | Sample | ||
|---|---|---|---|---|
| Blood | Tracheal | Urine | ||
| N = 93 | N = 59 | N = 3 | ||
| N (%) | N (%) | N (%) | N (%) | |
|
| 15 (28.8) | 2 (2.15) | 13 (22.03) | 0 |
|
| 7 (13.5) | 3 (3.23) | 4 (6.78) | 0 |
|
| 11 (21.2) | 0 | 11 (18.64) | 0 |
|
| 6 (11.5) | 1 (1.08) | 5 (8.47) | 0 |
|
| 5 (9.6) | 1 (1.08) | 4 (6.78) | 0 |
|
| 2 (3.8) | 1 (1.08) | 1 (1.69) | 0 |
|
| 1 (1.9) | 1 (1.08) | 0 | 0 |
|
| 0 | 0 | 0 | 0 |
|
| 3 (5.8) | 3 (3.23) | 0 | 0 |
|
| 0 | 0 | 0 | |
|
| 1 (1.9) | 1 (1.08) | 0 | 0 |
|
| 1 (1.9) | 1 (1.08) | 0 | 0 |
Overall susceptibilities of organisms isolated from samples taken off after 48–72 h of admission
| Bacterial species | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. susceptible/total number tested (%) | ||||||||||
|
|
|
|
|
|
|
|
|
|
| |
| Amikacin (30 µg) | 3/3 (100) | 0/1 (0) | 2/5 (40) | 4/6 (66.67) | 2/3 (67) | 1/1 (100) | – | – | – | – |
| Augmentin (20/10 µg) | 1/10 (10) | – | – | 0/2 (0) | 0/4 (0) | 0/1 (0) | – | – | – | – |
| Ampicillin (10 µg) | 0/11 (0) | – | – | 0/1 (0) | 0/4 (0) | – | – | – | – | 1/1 (100) |
| Cefotaxime (30 µg) | 1/4 (25) | – | – | 0/2 (0) | – | – | – | – | – | – |
| Cefuroxime (30 µg) | 1/11 (9.10) | – | – | – | 0/4 (0) | – | – | – | – | – |
| Ceftazidime (30 µg) | 1/9 (11.11) | 0/1 (0) | 2/5 (40) | 2/10 (20.00) | 0/4 (0) | 0/1 (0) | – | – | – | – |
| Ceftriaxone (30 µg) | 1/8 (12.50) | 1/1 (100) | – | 0/3 (0) | 0/4 (0) | 0/1 (0) | – | – | – | – |
| Cefepime (30 µg) | – | – | 1/4 (25) | 1/5 (20) | – | – | – | – | – | – |
| Ciprofloxacin (5 µg) | 3/9 (33.33) | 3/6 (50) | 3/6 (50) | 1/8 (12.05) | 1/4 (25) | 0/1 (0) | 1/1 (100) | 0/3 (0) | – | 0/1 (0) |
| Chloramphenicol (30 µg) | 2/9 (22.22) | 3/4 (75) | – | 0/2 (0) | 0/4 (0) | – | 0/1 (0) | 0/1 (0) | 1/1 (100) | 0/1 (0) |
| Co-trimoxazole (1.25/23.5 µg) | 0/10 (0) | 0/4 (0) | – | 0/8 (0) | 0/5 (0) | 0/1 (0) | 0/1 (0) | 0/2 (0) | – | – |
| Erythromycin (15 µg) | – | 1/6 (16.67) | – | – | 0/2 (0) | – | 0/1 (0) | 0/2 (0) | 1/1 (100) | – |
| Oxacillin (1 µg) | – | 1/4 (25) | – | – | 2/2 (100) | – | 0/1 (0) | 1/2 (50) | – | – |
| Tetracycline (30 µg) | 0/1 (0) | 2/3 (66.67) | 0/1 (0) | 0/1 (0) | – | – | – | 1/1 (100) | – | 0/1 (0) |
| Penicillin G (10 µg) | 1/4 (25) | – | – | 0/2 (0) | – | – | 0/2 (0) | 0/1 (0) | – | |
| Gentamicin (10 µg) | 2/10 (20.00) | 4/6 (66.67) | 3/6 (50) | 1/9 (11.11) | 0/5 (0) | 0/1 (0) | 1/1 (100) | 0/3 (0) | – | 1/1 (100) |
| Imipenem (10 µg) | 5/8 (62.5) | 1/1 (100) | 4/5 (80) | 5/6 (83) | 2/2 (100) | 1/1 (100) | – | – | – | – |
| Piperacillin tazobactam (100/10 µg) | 4/4 (100) | – | 3/6 (50) | 5/9 (55.56) | 2/4 (50) | – | – | – | – | – |
| Meropenem (10 µg) | 0/2 (0) | 1/1 (100) | 2/4 (50.00) | 3/3 (100) | – | – | – | – | – | |
| Vancomycin (30 µg) | – | 5/6 (83.3) | – | – | – | – | 1/1 (100) | 2/2 (100) | 1/1 (100) | 1/1 (100) |
Fig. 3Overall susceptibility patterns of organisms isolated at 48–72 h. The graph shows the proportion of isolates susceptible to each antibiotic and the number of isolates tested against each antibiotic
Multidrug resistant organism isolated after 48–72 h in the ICU
| Organism | No. of MDR isolates/total no. of isolates | % of isolates that were MDR |
|---|---|---|
|
| 11/15 | 73.3 |
|
| 7/11 | 63.6 |
|
| 3/6 | 50.0 |
|
| 4/7 | 57.1 |
|
| 3/5 | 60.0 |
|
| 1/2 | 50.0 |
| Overall | 29/50 | 58.0 |
Associated factors for infection after 48 h of admission in the ICU
| Risk factors | Not infected | Infected | Odds ratio (95% CI) | P value |
|---|---|---|---|---|
| N (%) | N (%) | |||
| Age group in years | ||||
| ≤30 | 30 (37.97) | 14 (43.75) | 1.27 (0.55–2.92) | 0.723 |
| 31–40 | 18 (22.78) | 8 (25.00) | 1.13 (0.43–2.94) | 0.983 |
| 41–50 | 8 (9.86) | 1 (3.13) | 0.27 (0.03–2.39) | 0.0412 |
| 51–60 | 10 (10.13) | 3 (9.38) | 0.71 (0.18–2.78) | 0.901 |
| >60 | 13 (16.46) | 6 (18.75) | 1.17 (0.40–3.41) | 0.969 |
| Sex | ||||
| Female | 34 (43.04) | 15 (46.88) | ||
| Male | 45 (56.96) | 17 (53.13) | 0.86 (0.38–1.95) | 0.717 |
| Referring within hospital | ||||
| No | 12 (15.19) | 5 (15.63) | ||
| Yes | 67 (84.81) | 27 (84.38) | 0.97 (0.31–3.01) | 0.935 |
| Admitting diagnosis | ||||
| Traumatic brain injury | 13 (16.46) | 12 (37.50) | 3.05 (1.20–7.72) |
|
| Haemorrhage | 2 (2.53) | 2 (6.25) | 2.57 (0.35–19.05) | 0.653 |
| Spinal cord injury | 2 (2.53) | 1 (3.13) | 1.242 (0.11–14.20) | 0.843 |
| Severe sepsis | 18 (22.78) | 3 (9.38) | 0.35 (0.10–1.29) | 0.163 |
| Cerebrovascular accident | 9 (11.39) | 5 (15.63) | 1.44 (0.44–4.69) | 0.747 |
| Cardiac condition | 7 (8.86) | 0 | – | – |
| Respiratory condition | 18 (22.78) | 3 (9.38) | 0.35 (0.10–1.29) | 0.163 |
| Kidney condition | 5 (6.33) | 3 (9.38) | 1.53 (0.34–6.82) | 0.837 |
| Obstetric condition | 1 (1.27) | 3 (9.38) | 8.07 (0.81–80.71) | 0.143 |
| Post Operative | 4 (5.06) | 0 | – | – |
| Antibiotics before admission | ||||
| No | 18 (22.78) | 4 (12.50) | ||
| Yes | 61 (77.22) | 28 (87.50) | 2.07 (0.64–6.67) | 0.334 |
| Ventilation | ||||
| No | 43 (54.43) | 7 (21.88) | ||
| Yes | 36 (45.57) | 25 (78.13) | 4.27 (1.65–11.01) |
|